INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neogen Corporation

The FDA said at least 20 horses died from serious infections linked to Neogen’s sterile-labeled Vet HYCOAT, and stated that Neogen initiated a voluntary recall in late January 2026. After the FDA announced a warning letter on September 29, 2026, Neogen shares fell $0.99, or 7.22%, to $12.73. Pomerantz LLP is investigating potential securities fraud or other unlawful business practices; the article does not establish wrongdoing.

Analysis

The incremental signal here is weak: a plaintiff firm’s investigation notice is not evidence of a filed or successful claim, and the reported share-price reaction occurred when the FDA warning became public—not on this November notice. The investment issue is the underlying quality-control and product-liability exposure, not the law-firm headline. Potential spillovers include customer scrutiny of Neogen’s quality systems and supplier qualification, plus a possible shift by equine veterinarians toward alternative wound-care products. But the article does not establish that HYCOAT is financially material to Neogen or that the defect extends beyond this product; do not extrapolate a subsidiary/product incident across the company without disclosures.

Near term, litigation notices may add volatility but are unlikely by themselves to establish a new earnings impairment. Over 1–3 months, monitor any complaint, FDA follow-up, recall expansion, or company disclosure quantifying remediation, claims, or lost sales. Over 6–18 months, repeat quality findings or customer attrition could raise compliance costs and weigh on trust in adjacent product lines; a contained incident with no broader findings would limit that risk. The contrarian point is that the initial repricing may already reflect the known regulatory shock, while this solicitation adds little new information. Conversely, investors may underweight reputational and monitoring costs if the issue proves broader than HYCOAT.

Key Decisions for Investors

• Do not initiate a short solely on the November 5 investigation notice. Treat it as low-incremental-information unless it is followed by a filed complaint, expanded FDA action, or material company disclosure.
• For existing NEOG exposure, keep risk sized to the unresolved product and quality-control uncertainty; reassess if the company reports broader recall scope, meaningful remediation costs, customer losses, or revised guidance.
• Watch for substitution toward competing equine wound-care products, but do not trade a named competitor without evidence of customer switching or a material revenue opportunity.
• Falsifiers: evidence that the issue is confined to HYCOAT with no broader quality-system findings would weaken the downside thesis; additional affected products, repeat regulatory findings, or quantified financial consequences would strengthen it.